Prof. Dr. Alexzander Asea, PhD, MBA is a biomedical-scientist, biotech entrepreneur, and manufacturing executive with more than two decades of global experience across immunology, vaccine development, biologics manufacturing, and translational medicine. He currently serves as Chief Executive Officer of Vaccine Access Initiative (VAi), where he is leading efforts to establish sustainable, GMP-compliant vaccine and advanced biologics manufacturing capacity in Africa.

Prof. Asea has authored over 300 scientific publications, books and editorials, holds multiple patents, and has raised significant public and private capital to advance biomedical innovation. His career spans senior academic appointments, industry leadership, and board-level governance, with a consistent focus on moving discoveries from laboratory to large-scale production in resource-constrained settings.

 Prof. Asea brings to AVMI a hands-on operator’s perspective, which combining policy insight, regulatory strategy, quality systems, and workforce development in order to support Africa’s transition toward vaccine manufacturing sovereignty and long-term health security.

Prof Dr Alexzander Asea was elected on to the AVMI Board at the 2026 AGM.